Skip to content

Coxiella burnetii (Phase I) (Antigen) 1227

$75.00

Summary

  • Virion/Serion Immunologics Antigen for research use (RUO)
  • Cost-effective due to standardized reagents
  • Lyophilized antigens, control antigens as well as positive and negative control sera simplify storage
  • Suitable screening test to identify acute infections
  • Compensation of seroprevalences allow high specificity
Weight 1 lbs
Dimensions 9 × 5 × 2 in
target

Coxiella burnetii phase I immunoglobulins

species reactivity

Coxiella burnetii (Q fever)

applications

CFT (Complement fixation test)

assay type

qualitative

available size

100 µL

Coxiella burnetii (Phase I) (Antigen) 1227

kit
Research area
Infectious Disease
Storage
Store at -65°C. Avoid freeze/thaw cycles. Sonicate before use.
Associated products
Coxiella burnetii Phase 2 IgG Control Serum (BC1312G)
Coxiella burnetii Phase 2 IgM Control Serum (BC1312M)
Coxiella burnetii IgA Phase I ELISA Kit (ESR1311A)
Coxiella burnetii IgG Phase I ELISA Kit (ESR1311G)
Coxiella burnetii IgG Phase II ELISA Kit (ESR1312G)
Coxiella burnetii IgM Phase II ELISA Kit (ESR1312M)
target relevance
Organism
Coxiella burnetii
Protein names
Coxiella burnetii
Structure and strains
Coxiella burnetii is an obligate intracellular bacterial pathogen, and is the causative agent of Q fever. The genus Coxiella is morphologically similar to Rickettsia, but with a variety of genetic and physiological differences. C. burnetii is a small Gram-negative, coccobacillary bacterium that is highly resistant to environmental stresses such as high temperature, osmotic pressure, and ultraviolet light. These characteristics are attributed to a small cell variant form of the organism that is part of a biphasic developmental cycle, including a more metabolically and replicatively active large cell variant form. It can survive standard disinfectants, and is resistant to many other environmental changes like those presented in the phagolysosome.
Detection and diagnosis
The diagnosis of Q fever is performed by the demonstration of specific antibodies directed against Coxiella burnetii. Due to variations in the lipopolysaccharide (LPS) structure on the surface of the pathogen, as the disease enters the chronic state, a serological differentiation of acute from chronic infections is possible. Due to the high sensitivity and specificity, the use of ELISA immunoassays is recommended by the World Health Organization (WHO). Following the regular course of an acute primary infection, specific IgM and IgG antibodies directed against the immunogenic phase 2 antigens can be demonstrated. IgG antibodies directed against phase 2 antigens often persist over several years. In the lead-up to a chronic infection, IgG and IgA antibodies directed against the phase 1 antigens appear, which are of diagnostic value particularly for the diagnosis of Q fever endocarditis

Data

Publications

Publications

pmid title authors citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BA102R01 protocol

Documents

#
KM0035 Safety Data Sheet QC certificate

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.